Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma
dc.contributor.author | Liu, Po‐hong | |
dc.contributor.author | Hsu, Chia‐yang | |
dc.contributor.author | Su, Chien‐wei | |
dc.contributor.author | Huang, Yi‐hsiang | |
dc.contributor.author | Hou, Ming‐chih | |
dc.contributor.author | Rich, Nicole E. | |
dc.contributor.author | Fujiwara, Naoto | |
dc.contributor.author | Hoshida, Yujin | |
dc.contributor.author | Singal, Amit G. | |
dc.contributor.author | Huo, Teh‐ia | |
dc.date.accessioned | 2020-10-01T23:31:12Z | |
dc.date.available | WITHHELD_13_MONTHS | |
dc.date.available | 2020-10-01T23:31:12Z | |
dc.date.issued | 2020-10 | |
dc.identifier.citation | Liu, Po‐hong ; Hsu, Chia‐yang ; Su, Chien‐wei ; Huang, Yi‐hsiang ; Hou, Ming‐chih ; Rich, Nicole E.; Fujiwara, Naoto; Hoshida, Yujin; Singal, Amit G.; Huo, Teh‐ia (2020). "Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma." Liver International 40(10): 2522-2534. | |
dc.identifier.issn | 1478-3223 | |
dc.identifier.issn | 1478-3231 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/162769 | |
dc.description.abstract | Background & AimsThrombocytosis is associated with more aggressive tumour biology in many malignancies. There are limited data in patients with hepatocellular carcinoma (HCC), which often occurs in patients with cirrhosis and portal hypertension. We aimed to explore the prognostic value of thrombocytosis in two cohorts of patients with HCC.MethodsWe included 3561 patients from Taiwan and 1145 patients from the USA. Thrombocytopenia was defined as platelet count < 150à 109/L and thrombocytosis as - ¥Â 300 à  109/L at HCC diagnosis. We used multivariable Cox proportional hazard models to identify independent predictors of survival.ResultsThrombocytosis was present in 9.0% and 6.9% of Taiwan and USA patients respectively. Compared to patients with normal platelet counts and those with thrombocytopenia, patients with thrombocytosis had larger tumours, increased vascular invasion and a higher proportion had extrahepatic metastases in both cohorts. In multivariable analysis, thrombocytosis (aHR 1.40, 95% CI 1.23- 1.60) and thrombocytopenia (aHR 1.13, 95% CI 1.04- 1.23) were both associated with worse survival after adjusting for age, gender, liver disease aetiology, Child- Pugh score, maximal tumour size, tumour nodularity, vascular invasion, lymph node or distant metastasis, performance status and alpha- fetoprotein level. Patients with thrombocytosis had a median survival of 6 and 4 months in the Taiwan and USA cohorts, compared to 32 and 14 months for those with normal platelet counts and 38 and 16 months for thrombocytopenic patients.ConclusionThrombocytosis is independently associated with increased tumour burden and worse overall survival among HCC patients. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | platelet count | |
dc.subject.other | prognosis | |
dc.subject.other | liver cancer | |
dc.title | Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/162769/2/liv14560.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/162769/1/liv14560_am.pdf | en_US |
dc.identifier.doi | 10.1111/liv.14560 | |
dc.identifier.source | Liver International | |
dc.identifier.citedreference | Durrleman S, Simon R. Flexible regression- models with cubic- splines. Stat Med. 1989; 8: 551 - 561. | |
dc.identifier.citedreference | van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis- related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol. 2017; 66: 485 - 493. | |
dc.identifier.citedreference | Pang Q, Qu K, Zhang J- Y, et al. The prognostic value of platelet count in patients with hepatocellular carcinoma: a systematic review and meta- analysis. Medicine (Baltimore). 2015; 94: e1431. | |
dc.identifier.citedreference | Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer </=2 cm: results from two Western centers. Hepatology. 2013; 57: 1426 - 1435. | |
dc.identifier.citedreference | Lee C- H, Lin Y- J, Lin C- C, et al. Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma. Liver Int. 2015; 35: 2327 - 2336. | |
dc.identifier.citedreference | Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004; 10: 2472 - 2477. | |
dc.identifier.citedreference | Lee M, Chung GE, Lee J- H, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology. 2017; 66: 1556 - 1569. | |
dc.identifier.citedreference | Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018; 4: 1683 - 1690. | |
dc.identifier.citedreference | Lee P- C, Yeh C- M, Hu Y- W, et al. Antiplatelet therapy is associated with a better prognosis for patients with hepatitis b virus- related hepatocellular carcinoma after liver resection. Ann Surg Oncol. 2016; 23: 874 - 883. | |
dc.identifier.citedreference | Liu P- H, Hsu C- Y, Hsia C- Y, et al. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2016; 64: 601 - 608. | |
dc.identifier.citedreference | Rich NE, Hester C, Odewole M, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019; 17 ( 551- 559 ): e551. | |
dc.identifier.citedreference | Omata M, Cheng A- L, Kokudo N, et al. Asia- Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11: 317 - 370. | |
dc.identifier.citedreference | Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9: 64 - 70. | |
dc.identifier.citedreference | Wiesner R, Edwards E, Freeman R, et al. Model for end- stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003; 124: 91 - 96. | |
dc.identifier.citedreference | Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence- based approach- the ALBI grade. J Clin Oncol. 2015; 33: 550 - 558. | |
dc.identifier.citedreference | European Association For The Study Of The Liver, European Organisation For Research and Treatment of Cancer. EASL- EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908 - 943. | |
dc.identifier.citedreference | Harrell FE Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988; 80: 1198 - 1202. | |
dc.identifier.citedreference | Haemmerle M, Stone RL, Menter DG, Afshar- Kharghan V, Sood AK. The platelet lifeline to cancer: Challenges and opportunities. Cancer Cell. 2018; 33: 965 - 983. | |
dc.identifier.citedreference | Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta- analysis. PLoS Medicine. 2014; 11: e1001624. | |
dc.identifier.citedreference | Choi DT, Kum H- C, Park S, et al. Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis. Clin Gastroenterol Hepatol. 2019; 17 ( 976- 987 ): e974. | |
dc.identifier.citedreference | Singal AG, Yopp A, S. Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: A systematic review. J Gen Intern Med. 2012; 27: 861 - 867. | |
dc.identifier.citedreference | Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012; 5: 1124 - 1130. | |
dc.identifier.citedreference | Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012; 109: E2165 - 2172. | |
dc.identifier.citedreference | Sitia G, Iannacone M, Guidotti LG. Anti- platelet therapy in the prevention of hepatitis B virus- associated hepatocellular carcinoma. J Hepatol. 2013; 59: 1135 - 1138. | |
dc.identifier.citedreference | Lee T- Y, Hsu Y- C, Tseng H- C, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med. 2019; 179: 633 - 640. | |
dc.identifier.citedreference | Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA. 2014; 111: E3053 - 3061. | |
dc.identifier.citedreference | Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378 - 390. | |
dc.identifier.citedreference | Li JH, Wang Y, Xie XY, et al. Aspirin in combination with TACE in treatment of unresectable HCC: a matched- pairs analysis. Am J Cancer Res. 2016; 6: 2109 - 2116. | |
dc.identifier.citedreference | Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: 2018 Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018; Available from https://gco.iarc.fr/today, accessed 07/17/2019. | |
dc.identifier.citedreference | Singal AG, Mittal S, Yerokun OA, et al. Hepatocellular carcinoma screening associated with early tumor detection and improved survival among patients with cirrhosis in the US. Am J Med. 2017; 130 ( 1099- 1106 ): e1091. | |
dc.identifier.citedreference | Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018; 68: 526 - 549. | |
dc.identifier.citedreference | Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10- year outcome and prognostic factors. Am J Gastroenterol. 2012; 107: 569 - 577; quiz 578. | |
dc.identifier.citedreference | Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann Surg. 2015; 261: 947 - 955. | |
dc.identifier.citedreference | Rich NE, Yopp AC, Singal AG, Murphy CC. Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States. Clin Gastroenterol Hepatol. 2019. | |
dc.identifier.citedreference | Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2019. | |
dc.identifier.citedreference | Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012; 366: 610 - 618. | |
dc.identifier.citedreference | Baranyai Z, Josa V, Toth A, et al. Paraneoplastic thrombocytosis in gastrointestinal cancer. Platelets. 2016; 27: 269 - 275. | |
dc.identifier.citedreference | Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018; 68: 723 - 750. | |
dc.identifier.citedreference | European association for the study of the liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; 69: 406 - 460. | |
dc.identifier.citedreference | Peck- Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017; 37: 778 - 793. | |
dc.identifier.citedreference | Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci. 2013; 58: 1790 - 1796. | |
dc.identifier.citedreference | Scheiner B, Kirstein M, Popp S, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer. 2019; 8: 203 - 217. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.